Surgical management of GIST in the era of Gleevec®;Traitement chirurgical des GIST à l'heure du Glivec®

Annales de Chirurgie

Volumn 130, Issue 3, 2005, Pages 144-151

  Bonvalot, S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Gastro intestinal stromal tumor; GIST; Gleevec ; Surgery

Indexed keywords

IMATINIB;

CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER SURGERY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 15744365229     PISSN: 00033944     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anchir.2004.10.012     Document Type: Short Survey

References (39)

1. G.D. Demetri Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options Semin. Oncol. 28 5 Suppl 17 2001 19 26
2. M.C. Heinrich, C.L. Corless, G.D. Demetri, C.D. Blanke, M. Von Mehren, and H. Joensuu Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol. 21 23 2003 4342 4349
3. S. Singer, B.P. Rubin, M.L. Lux, C.J. Chen, G.D. Demetri, and C.D. Fletcher Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors J Clin Oncol. 20 18 2002 3898 3905
4. R.P. Dematteo, M.C. Heinrich, W.M. El-Rifai, and G. Demetri Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum. Pathol. 33 5 2002 466 477
5. H. Joensuu, P.J. Roberts, M. Sarlomo-Rikala, L.C. Andersson, P. Tervahartiala, D. Tuveson, and S. Silberman Brief Report: Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor N. Engl. J. Med. 344 14 2001 1052 1056
6. A.T. Van Oosterom, I.R. Judson, J. Verweij, S. Stroobants, H. Dumez, E. Donato di Paola European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Update of phase I study of imatinib (STI 571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group Eur. J. Cancer 38 Suppl 5 2002 S83 S87
7. ®) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target.Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study Eur. J. Cancer 39 14 2003 2006 2011
8. G.D. Demetri, M. Von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, and P. Roberts Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 7 2002 472 480
9. S. Silberman, and H. Joensuu Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts Eur J Cancer 38 Suppl 5 2002 S66 S69
10. J.R. Zalberg, J. Veirveij, P Casali, A Le Cesne, P Reichardt, JY Blay et al. Outcome of patients with advanced gastrointestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800 mg after progression on 400mg An international intergroup study on the EORTC,ISG, and AGITG Proceedings ASCO 2004 vol 23 abstract 9004.
11. A.J. Balaton, J.M. Coindre, and F. Cvitkovic Tumeurs stromales digestives Gastroenterol. Clin. Biol. 25 2001 473 482
12. K.A. Yao, M.S. Talamonti, R.L. Langella, N.M. Schindler, S. Rao, and W. Small Jr. Primary gastrointestinal sarcomas: analysis of prognostic factors and results of surgical management Surgery 128 4 2000 604 612
13. J.P. Pierie, U. Choudry, A. Muzikansky, B.Y. Yeap, W.W. Souba, and M.J. Ott The effect of surgery and grade on outcome of gastrointestinal stromal tumors Arch. Surg. 136 4 2001 383 389
14. E.H. Ng, R.E. Pollock, M.F. Munsell, E.N. Atkinson, and M.M. Romsdalh Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging Ann. Surg. 215 1 1992 68 77
15. P.C. McGrath, J.P. Neifeld, W. Lawrence Jr., S. Kay, J.S. Horsley, and G.A. Parker Gastrointestinal sarcomas. Analysis of prognostic factors Ann. Surg. 206 6 1987 706 710
16. R.P. De Matteo, J.J. Lewis, D. Leug, S. Mudan, J.M. Woodruff, and M. Brennan Two hundred gastrointestinal stromal tumors:: recurrence patterns and prognostic factors for survival Ann. Surg. 231 1 2000 51 58
17. M. Miettinen, and J. Lasota Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis Virchows Arch 438 1 2001 1 12
18. C.L. Corless, L. McGreevey, A. Haley, A. Town, and M.C. Heinrich KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size Am. J. Pathol. 160 5 2002 1567 1572
19. M. Miettinen, W.H.L. El-Rifai, L. Sobin, and J. Lasota Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review Hum Pathol. 33 5 2002 478 483
20. C.D. Fletcher, J.J. Berman, C. Corless, F. Gorstein, J. Lasota, and B.J. Longley Diagnosis of gastrointestinal stromal tumors: A consensus approach Hum. Pathol. 33 5 2002 459 465
21. K.A. Yao, M.S. Talamonti, R.L. Langella, N.M. Schindler, S. Rao, W. Small, and Joehl Primary gastrointestinal sarcomas: analysis of prognostic factors and results of surgical management Surgery 128 4 2000 604 612
22. T. Aparicio, V. Boige, J.C. Sabourin, A. Le Cesne, P. Crenn, and M. Ducreux Prognostic factors after complete resection of primary gastro intestinal stromal tumors Eur J Surg Oncol 30 10 2004 1101 1106
23. S. George, and J. Desai Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors Curr. Treat. Options Oncol. 3 6 2002 489 496
24. F. Duffaud, and J.Y. Blay Gastrointestinal stromal tumors: biology and treatment Oncology 65 3 2003 187 197
25. S.S. Mudan, K.C. Conlon, J.M. Woodruff, J.J. Lewis, and M.F. Brennan Salvage surgery for patients with recurrent gastrointestinal sarcoma: prognostic factors to guide patient selection Cancer 88 1 2000 66 74
26. B.E. Plaat, H. Hollema, W.M. Molenaar, G.H. Torn Broers, J. Pijpe, and M.F. Mastik Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrresistance proteins J. Clin. Oncol. 18 18 2000 3211 3220
27. D.P. Jacques, D.G. Colt, E.S. Caspar, and M.F. Brennan Hepatic metastases from soft tissue sarcoma Ann. Surg. 221 1995 392 397
28. R.P. De Matteo, A. Shah, Y. Fong, W.R. Janargin, L.H. Blumgart, and M.F. Brennan Results of hepatic resections for sarcoma metastatic to liver Ann. Surg 234 2001 540 547
29. ®) Eur. J. Cancer 39 14 2003 2012 2020
30. N Lassau, M Muraglia, J.Leclere, S. Bonvalot, D Vanel, C. Robert et al. Doppler ultasonographywith perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: results of a prospective study Proceedings ASCO 2004 vol 23 abstact 9048.
31. ®: qui b́ńficie actuellement de la chirurgie ? Gastroenterol. Clin. Biol. 28 A 2004 103
32. R.S. Benjamin, C.D. Blanke, J.Y. Blay, S. Bonvalot, and B. Eisenberg Management of gastro intestinal stromal tumors in the imatinib era: selected cases studies The Oncologist 2004 sous presse
33. S. Silberman, and H. Joensuu Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts Eur. J. Cancer 38 Suppl 5 2002 S66 S69
34. C.L. Scaife, K.K. Hunt, S.R. Patel, R.S. Benjamin, M.A. Burgess, and L.L. Chen Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am. J. Surg. 186 6 2003 665 669
35. S.Bauer, JT Hartman, H Lang, G Antoch, O Dirsh; P Ebeling et al. Imatinib may enable complete resection in previously unresectable or metastatic GISTS Proceedings ASCO 2004 vol 23 abstact 9023.
36. Demetri G. Symposium GIST, ECCO 12 Septembre 2003; Communication orale.
37. Desai J., S Shankar, C Heinrich, JA Fletcher et al. Clonal evolution of resistance to imatinib in patients with gastro intestinal tumors: molecular and radiologic evaluation of new lesions: Proceedings ASCO 2004 vol 23 abstract 3010.
38. Dileo P, R Randhawa, E Vanonnenberg, S Shankar, J Desai, A Morgan, K Tuncali, G Demetri Safety and efficacy of percutaneous radiofrequency ablation (RFA) in patients with GIST with clonal evolution of lesions refractory to imatinib Proceedings ASCO 2004 vol 23 abstract 9024.
39. JY Blay, P Berthaud, D Perol, I Ray coquard, B Bui, F Duffaud, A Braud, M Rios, F Ducimetiere, A Le Cesne et al. Continuous versus intermittent imatinib treatment in advanced GIST after one year: a prospective phase III randomised trial of the French sarcoma group. Proceedings ASCO 2004 vol 23 abstract 9006.